Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026. With ...

Alumis also has a second TYK2 drug (A-005) in a Phase I trial for neuroinflammation. As all other products under development are still in the pre-clinical phase, they won’t be discussed here.

Alumis's lead product candidate, ESK-001, has shown promising results in a Phase 2 psoriasis study and is expected to generate multi-billion dollar revenues if approved.

Alumis Inc. completed patient enrollment in its Phase 3 trials for ESK-001, targeting moderate-to-severe plaque psoriasis. Quiver AI Summary. Alumis Inc. has announced the successful completion of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that ...

Alumis Inc. – Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy ...

Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, ...

Alumis is making up some of that by selling 2.5 million shares at the IPO price to one of its largest investors. This concurrent private placement brings Alumis an additional $40 million.

Alumis has reeled in an eye-watering $259 million series C, financing that will help launch a phase 3 psoriasis trial for lead asset ESK-001.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

June 28 (Reuters) - Shares of biopharmaceutical firm Alumis (ALMS.O), opens new tab opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday. A long ...